Literature DB >> 18186706

Herpes simplex: insights on pathogenesis and possible vaccines.

David M Koelle1, Lawrence Corey.   

Abstract

Abstract Herpes simplex viruses are evolutionarily ancient and ubiquitous. In the past 20 years, there has been increasing recognition of a worldwide pandemic of HSV-2 infection. Moreover, HSV-2 prevalence has increased despite fairly widespread use of antiviral drugs for HSV. The success of HSV-1 and HSV-2 stems from latency within long-lived neurons and frequent mucocutaneous shedding. The generally mild medical consequences of HSV infection reflect a functional equilibrium between host and microbe in most immunocompetent persons. However, significant gaps in our knowledge of the correlates of disease severity and HSV immune evasion are limiting rational advances in these areas. Human genetic studies are gradually outlining important innate responses, while recent imaging and biopsy studies have begun to show that the temporal and spatial anatomic interplay between virus reactivation and host immune response may be important in reactivations and disease expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18186706     DOI: 10.1146/annurev.med.59.061606.095540

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  97 in total

1.  Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.

Authors:  Christopher S Morello; Michael S Levinson; Kimberly A Kraynyak; Deborah H Spector
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  Regulation of herpes simplex virus type 1 thymidine kinase gene expression by thyroid hormone receptor in cultured neuronal cells.

Authors:  Shao-Chung V Hsia; Rajeswara C Pinnoji; Gautam R Bedadala; James M Hill; Jayavardhana R Palem
Journal:  J Neurovirol       Date:  2010-02       Impact factor: 2.643

3.  Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons.

Authors:  Jieliang Li; Shuxian Hu; Lin Zhou; Li Ye; Xu Wang; Jie Ho; Wenzhe Ho
Journal:  Glia       Date:  2010-09-27       Impact factor: 7.452

4.  An in silico approach to design potential siRNA molecules for ICP22 (US1) gene silencing of different strains of human herpes simplex 1.

Authors:  Suza Mohammad Nur; Mohammad Al Amin; Rashel Alam; Md Anayet Hasan; Md Amzad Hossain; Adnan Mannan
Journal:  J Young Pharm       Date:  2013-06-20

5.  SOCS1/3 expression levels in HSV-1-infected, cytokine-polarized and -unpolarized macrophages.

Authors:  Adam Craig Reichard; Nagarjuna Reddy Cheemarla; Nancy Jane Bigley
Journal:  J Interferon Cytokine Res       Date:  2014-06-23       Impact factor: 2.607

6.  Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.

Authors:  Marina Boukhvalova; Jamall McKay; Aissatou Mbaye; Hannah Sanford-Crane; Jorge C G Blanco; Ashley Huber; Betsy C Herold
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

7.  Viral kinetics of genital herpes: a molecular probe into host-viral interactions.

Authors:  Thomas C Quinn
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

8.  Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection.

Authors:  Melanie Merbah; Andrea Introini; Wendy Fitzgerald; Jean-Charles Grivel; Andrea Lisco; Christophe Vanpouille; Leonid Margolis
Journal:  Am J Reprod Immunol       Date:  2011-01-12       Impact factor: 3.886

9.  Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.

Authors:  Xiuli Zhang; Florence A Castelli; Xiaoming Zhu; Michele Wu; Bernard Maillère; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

10.  Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers.

Authors:  Bulbulgul Aumakhan; Charlotte A Gaydos; Thomas C Quinn; Chris Beyrer; Lorie Benning; Howard Minkoff; Daniel J Merenstein; Mardge Cohen; Ruth Greenblatt; Marek Nowicki; Kathryn Anastos; Stephen J Gange
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.